COMBINATION THERAPY COMPRISING AN INHIBITOR OF JAK, CDK, AND PIM

摘要

The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.

主权项

1. A pharmaceutical combination comprising
(a) Ruxolitinib (Compound A) or a pharmaceutically acceptable salt thereof, (b) Compound B or a pharmaceutically acceptable salt thereof, and (c) Compound C or a pharmaceutically acceptable salt thereof.